Frontlight ResearchEarly access
TerminatedPhase 3
ARrest RESpiraTory Failure From PNEUMONIA
Key facts
- Who runs it
- Stanford University
- Where
- Baltimore, Birmingham, Gainesville, Jacksonville, New Orleans, New York, Palo Alto, Philadelphia, Rochester, Scottsdale, and Tucson, United StatesSee the 12 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 465 people enrolled
- Started
- 1 Jun 2020
- Ended
- 22 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Inhaled budesonide and formoterol
- Inhaled placebo
- Record updated
- 6 August 2026
- Why it stopped
- Per DSMB's review of interim analysis, the study has reached the pre-specified futility criteria
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Patients 18 years or older with
- Severe pneumonia defined as:
- Hospitalization for acute (defined as ≤ 14 days) onset of symptoms (cough, sputum production, or dyspnea), AND 2. Radiographic evidence of pneumonia by chest radiograph or CT scan, AND 3. One of the following:
- Evidence of systemic inflammation (temperature < 35◦C or > 38◦C OR WBC > or < upper or lower limits for site OR procalcitonin > 0.5 mcg/L), OR
- Known current immunosuppression preventing inflammatory response, OR
- High clinical suspicion of pneumonia with microbiologic confirmation of infection. Microbiologic confirmation will include a positive nasal swab for a known respiratory virus; a sputum culture growing a likely pathogenic organism plus moderate or greater WBCs (not required for immunocompromised patients); or a positive blood culture with a likely pathogenic organism - e.g., ¼ vials with S. Epidermidis would NOT qualify); AND Hypoxemia defined as new requirement for daytime supplemental oxygen with SpO2 < 92% on room air, ≤ 96% on ≥ 2 L/min oxygen, or > 6L/min or non-invasive ventilation regardless of SpO2 at enrollment. Patients admitted with pneumonia but not meeting criteria for hypoxemia will be followed for up to 48 hours from ED admission to enrolling hospital to assess for development of qualifying hypoxemia
Who cannot take part
- Intubation (or impending intubation) prior to enrollment; Patients receiving HFNC oxygen or NIV prior to enrollment are not excluded
- A condition requiring inhaled corticosteroids or beta-agonists (patients receiving inhaled beta-agonists in the ED without an established indication will be eligible if treating clinician is willing to discontinue subsequent treatments)
- Chronic systemic steroid therapy equivalent to >10 mg prednisone
- COVID-19 positive patients receiving > 6 mg dexamethasone (40 mg prednisone equivalent dose) except for stress dose steroids for septic shock
- Non-COVID-19 pneumonia patients receiving systemic steroid > 10 mg prednisone except for stress dose steroids for septic shock
- Chronic lung or neuromuscular disease requiring daytime oxygen or mechanical ventilation other than for obstructive sleep apnea (OSA) or obesity hypoventilation syndrome
- Contraindication or allergy to inhaled corticosteroids or beta-agonists
- Patients with heart rate > 130 bpm, ventricular tachycardia or new supraventricular tachycardia within last 4 hours will be potentially eligible for enrollment after the condition has resolved
- Patients with K+ < 3.0 will be potentially eligible for enrollment after the condition has resolved
- Inability to randomize within 48 hours of presentation to enrolling hospital (randomization beyond 24 hours will be limited to patients with persistent hypoxemia defined by an SpO2 < 97% while on > 3L/min O2)
- Not anticipated to survive > 48 hours or not expected to require > 48 hours of hospitalization
- Patient not committed to full support other than intubation or resuscitation (i.e., DNR/DNI status allowed)
- Pregnancy
- Incarcerated individual
- Physician refusal of consent to protocol
- Patient/surrogate refusal of consent to protocol
Where in United States
- Johns Hopkins University - Main Campus & BayviewBaltimore, United States
- University of MarylandBaltimore, United States
- University of Alabama Birmingham - Main & HighlandsBirmingham, United States
- University of FloridaGainesville, United States
- Mayo Clinic- JacksonvilleJacksonville, United States
- Tulane University - Main & BUMCNew Orleans, United States
- New York University Langone HealthNew York, United States
- Stanford UniversityPalo Alto, United States
- Temple UniversityPhiladelphia, United States
- Mayo Clinic - RochesterRochester, United States
- Mayo Clinic ScottsdaleScottsdale, United States
- University of Arizona - Main & South CampusTucson, United States
About the trial
What the trial wants to find out
This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.
The 2 groups in the trial
- PlaceboPlacebo, for comparison
4 ml aerosolized 0.9% saline every 12 hours x 10 doses
Treatment: Inhaled placebo
- InterventionExisting treatment, for comparison
aerosolized formoterol (20 mcg/2 ml) and budesonide (1.0 mg/2 ml) every 12 hours x 10 doses
Treatment: Inhaled budesonide and formoterol
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- ARrest RESpiraTory Failure From PNEUMONIA (ARREST PNEUMONIA)
- Publications
- The ARREST Pneumonia Clinical Trial. Rationale and Design.Annals of the American Thoracic Society, 2021
- Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?The Lancet. Respiratory medicine, 2020
- Record updated
- 6 August 2026